Avinger (NASDAQ:AVGR) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR) in a report published on Sunday morning. The firm issued a hold rating on the medical device company’s stock.

Avinger Stock Performance

AVGR opened at $0.72 on Friday. The company has a market cap of $2.38 million, a price-to-earnings ratio of -0.06 and a beta of 1.15. Avinger has a one year low of $0.39 and a one year high of $5.45. The business’s fifty day moving average is $0.81 and its two-hundred day moving average is $1.10.

Avinger (NASDAQ:AVGR) last released its quarterly earnings results on Thursday, November 7th. The medical device company reported ($1.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.21. The business had revenue of $1.65 million during the quarter, compared to the consensus estimate of $1.60 million. Avinger had a negative return on equity of 5,527.11% and a negative net margin of 261.06%. During the same quarter in the previous year, the company posted ($2.92) EPS. On average, analysts predict that Avinger will post -4.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Avinger stock. Armistice Capital LLC purchased a new position in shares of Avinger, Inc. (NASDAQ:AVGR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned approximately 2.57% of Avinger as of its most recent filing with the Securities and Exchange Commission (SEC). 18.30% of the stock is currently owned by institutional investors.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.